Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Baxter to pay $18...

    Baxter to pay $18 million over mold at North Carolina plant

    Written by supriya kashyap kashyap Published On 2017-01-15T11:31:46+05:30  |  Updated On 15 Jan 2017 11:31 AM IST
    Baxter to pay $18 million over mold at North Carolina plant

    Washington : Baxter International has agreed to pay $18 million to resolve its criminal and civil liability over claims its unit ignored mold in air filters at a plant where sterile intravenous solutions were made, the U.S. Justice Department said.


    The resolution includes a deferred prosecution agreement and penalties and forfeiture totaling $16 million and a civil settlement under the False Claims Act with the federal government totaling approximately $2.158 million, the Justice Department said in a statement.


    The government charged that managers at Baxter Healthcare Corp's North Cove plant in Marion, North Carolina, ignored an employee's warning that mold was found in air filters in the ceiling of the room where sterile intravenous solutions were manufactured, the statement said.


    There was no evidence, however, that the mold affected the quality of the IV solutions, which were manufactured from July 2011 to November 2012, the department said.


    A Baxter spokeswoman said the handling of the mold concerns "was not consistent with Baxter's standards" and the company had made some changes as a result.


    "We took a number of actions to address these issues, including terminating several members of the facility’s management team and enhancing the training and compliance processes for employees throughout the facility," Baxter spokeswoman Deborah Spak said in a statement.


    Problems with mold in Baxter's air filters were revealed several years ago, after FDA inspectors issued the company a warning letter about the problem.


    "We are especially concerned that you have not identified the root cause that allowed the mold to proliferate" to a level that was too numerous to count, the FDA said in its May 2013 letter.


    The letter also said the mold problem represented a "repeat violation" from a 2012 inspection.


    The civil portion of Thursday's settlement came about after Christopher Wall, a Baxter employee, blew the whistle and filed a False Claims Act lawsuit.


    He will recover a little more than $431,500 from the case.


    While the quality of the IV solutions were not affected by the mold in this case, the company has had a number of recall product recalls over the last few years in connection with quality problems.


    Some lots of IV solutions, for instance, were previously recalled after a customer discovered an insect.


    Baxter also in 2014 recalled some of its dialysis products due to mold.

    agreementBaxterBaxter Healthcare Corp's North CoveDeborah SpakFalse Claims Actfederal governmentUS Justice Department
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok